Abbott reported $920M in Net Income for its fiscal quarter ending in September of 2026.





Net Income Change Date
Abbott USD 920M 8M Sep/2026
Agilent USD 362M 23M Jun/2026
AtriCure USD 4.06M 4.89M Sep/2026
Baxter International USD 294M 168M Sep/2026
Becton, Dickinson and Co. USD 696M 319M Sep/2026
Bio-Rad Laboratories USD 371.4M 898.5M Jun/2026
Boston Scientific USD 582M 325M Sep/2026
Cooper Companies USD 432.8M 510.7M Jun/2026
Danaher USD 1.24B 365M Sep/2026
Dexcom USD 249.1M 49.6M Jun/2026
Edwards Lifesciences USD 307.5M 65.6M Sep/2026
Globus Medical USD 141.17M 10.4M Sep/2026
Insulet USD 141.1M 46.1M Sep/2026
Integra LifeSciences USD 14.85M 10.37M Sep/2026
Intuitive Surgical USD 522.8M 295.3M Sep/2026
J&J USD 210M 5.32B Sep/2026
Medtronic USD 1.47B 227M Jun/2026
Merit Medical Systems USD 38.8M 2.19M Jun/2026
Pfizer USD 3.24B 3.49B Sep/2026
Smith & Nephew USD 303M 10M Jun/2026
Solventum Corp USD -12M 104M Sep/2026
Stryker USD 1.28B 531M Jun/2026
Tandem Diabetes Care USD -7.08M 14.08M Sep/2026
Teleflex USD 927.43M 827.73M Sep/2026
Terumo JPY -15.81B 86.24B Sep/2026
Thermo Fisher Scientific USD 1.72B 15M Sep/2026
Zimmer Biomet Holdings USD 191.6M 6.7M Sep/2026